EKSO BIONICS (EKSO) AI Stock Analysis

• Market Cap: $8.44M
• Dividend Yield: N/A
• Average Volume (3M): 3.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: -2.06%
• EPS Growth: 49.72%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.12
• Shares Outstanding: 29,042,974
• 10 Day Avg. Volume: 11,677,689
• 30 Day Avg. Volume: 3,983,280
• PEG Ratio: -0.08
• Price to Book (P/B): 0.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.52
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.50
• Price Target Upside: 900.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 49 Neutral
• Price Target: $0.50 ▲( 100.00% Upside)

EKSO BIONICS' overall stock score reflects the ongoing financial challenges and bearish technical indicators, which are partially offset by some positive developments from the latest earnings call. The company's efforts to improve profitability and strategic partnerships offer potential upside, but the current financial and market conditions suggest caution. The valuation remains unattractive due to negative earnings, and the stock is currently experiencing downward pressure as indicated by technical analysis.

Positive Factors

Financial Outlook

Revenue growth is expected in both the legacy enterprise business and Indego Personal, indicating a positive outlook for 2025.

Product Distribution

Ekso continues to expand its distribution network for the Ekso Indego Personal product.

Strategic Partnerships

Strategic partnerships have been formed to broaden access to Ekso Indego Personal and navigate the reimbursement process, potentially expanding the market and driving long-term value for Ekso.

Negative Factors

Customer Budget Cuts

Softer enterprise revenue due to customer budget cuts.

Reimbursement Process Challenges

Numerous activities must take place before a Medicare enrollee receives a unit, complicating the reimbursement process.

Revenue Decline

Ekso Bionics reported a 2% year-over-year decline in total revenue for 2024, mainly due to lower enterprise sales.

EKSO BIONICS Business Overview & Revenue Model

Company Description

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

How the Company Makes Money

Ekso Bionics generates revenue through the sale and lease of its exoskeleton products, primarily targeting healthcare facilities, rehabilitation centers, and industrial clients. A significant portion of its earnings comes from its flagship product line, EksoNR, which is used in medical rehabilitation to aid patients with spinal cord injuries, stroke, and other neurological conditions. Additionally, the company offers the EksoVest and EksoZeroG for industrial applications, designed to reduce fatigue and improve worker safety in demanding physical environments. Ekso Bionics also benefits from strategic partnerships and collaborations with healthcare institutions and industrial companies, which help expand its market reach and drive product adoption. The company occasionally receives grants and funding for research and development, further supporting its revenue streams.

EKSO BIONICS Financial Statement Overview

Summary

EKSO BIONICS faces ongoing financial challenges characterized by negative profitability and cash flow metrics. While there are signs of improvement in operational efficiency and cash flow management, the company needs to address its persistent losses and reliance on external financing. The moderate leverage and stable equity position offer some stability, yet achieving consistent revenue growth and profitability remains crucial for long-term sustainability.

Income Statement

EKSO BIONICS has shown a volatile revenue trajectory with a slight revenue decline of 1.94% from 2023 to 2024. The gross profit margin improved to 53.06% in 2024 from 49.68% in 2023, indicating efficiency in controlling direct costs. However, the company continues to face challenges with profitability, as evidenced by a negative net profit margin of -63.21% in 2024, despite improving from -83.17% in 2023. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

EKSO BIONICS' balance sheet reflects a stable equity position with an equity ratio of 47.68% as of 2024. The debt-to-equity ratio stands at 0.47, indicating moderate leverage, which has slightly decreased from 0.57 in 2023. However, the return on equity remains negative at -89.17% due to persistent net losses, highlighting a challenging environment for shareholder returns.

Cash Flow

The cash flow statement reveals a negative free cash flow for 2024, although it improved by 19.46% compared to 2023. The operating cash flow to net income ratio is 0.87, suggesting that operational cash generation is not sufficient to cover net losses. The company is heavily reliant on financing activities to support cash flow needs.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
17.54M	17.93M	18.28M	12.91M	11.25M	8.88M
	Gross Profit
9.37M	9.51M	9.08M	6.21M	6.75M	5.07M
	EBIT
-10.64M	-10.46M	-15.11M	-15.56M	-13.83M	-12.86M
	EBITDA
-9.93M	-9.45M	-13.20M	-14.04M	-9.09M	-15.07M
	Net Income Common Stockholders
-10.79M	-11.33M	-15.20M	-14.60M	-8.43M	-16.95M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.80M	6.49M	8.64M	20.52M	40.41M	12.86M
	Total Assets
28.96M	26.65M	28.92M	40.90M	49.17M	20.60M
	Total Debt
6.84M	5.98M	7.17M	7.50M	2.22M	3.86M
	Net Debt
-1.96M	-510.00K	-1.47M	-13.02M	-38.18M	-9.01M
	Total Liabilities
14.91M	13.95M	16.31M	15.46M	11.95M	16.16M
	Stockholders Equity
14.05M	12.71M	12.61M	25.44M	37.22M	4.43M
Cash Flow		Free Cash Flow
-8.37M	-9.88M	-12.21M	-14.88M	-11.21M	-8.76M
	Operating Cash Flow
-8.35M	-9.85M	-12.05M	-14.69M	-11.16M	-8.76M
	Investing Cash Flow
-39.00K	-37.00K	-157.00K	-5.17M	-59.00K	0.00
	Financing Cash Flow
7.64M	7.77M	348.00K	176.00K	38.71M	10.70M

EKSO BIONICS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKSO, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.42, and below the 200-day MA of 0.72, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 31.61 is Neutral, neither overbought nor oversold. The STOCH value of 8.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EKSO.

EKSO BIONICS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
EKSO	49 Neutral	$8.44M	―	-80.71%	―	-2.06%	49.72%
MLSS	48 Neutral	$82.40M	―	-88.36%	―	-9.13%	30.04%
HBIO	44 Neutral	$14.87M	―	-138.80%	―	-14.41%	-549.88%
MBOT		$95.31M	―	-66.48%	―	―	―
AKYA	46 Neutral	$52.87M	―	-354.27%	―	-14.55%	34.87%
FEMY	39 Underperform	$29.42M	―	-239.87%	―	61.97%	-6.89%

EKSO BIONICS Corporate Events

Ekso Bionics Announces Reverse Stock Split Approval

On May 16, 2025, Ekso Bionics’ stockholders approved a reverse stock split at a 1-for-15 ratio, which will take effect on June 2, 2025. The split aims to increase the company’s stock price to meet Nasdaq’s minimum bid requirement, reducing the number of outstanding shares from approximately 35.5 million to 2.4 million.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Ekso Bionics Approves Reverse Stock Split Plan

On May 16, 2025, Ekso Bionics held its Annual Meeting of Stockholders where several key proposals were approved, including a reverse stock split at a ratio of 1-for-15, effective May 27, 2025. This move is primarily intended to increase the per-share trading price and help the company regain compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.